Site Search
Displaying results 241 - 250 of 573
Resource | Infographics,
While scaling up access to all treatment and prevention options that currently exist is essential, it is not sufficient. There remains a critical need for additional options. In addition to the introduction of oral-TDF based PrEP and the open-lable extension studies of the vaginal dapivirine ring, there are a number of efficacy trials planned or underway. They're tackling virtually every intervention—from next-generation PrEP in the form of F/TAF, a drug that will soon be tested for efficacy as daily oral PrEP, to long-acting injectables, vaccines and antibody-mediated prevention.
Resource | Publications,
The Global Forum on MSM & HIV (MSMGF) was founded in 2006 at the Toronto International AIDS Conference by an international group of activists concerned about the disproportionate HIV disease burden being shouldered by gay, bisexual and other men who have sex with men worldwide. The silence at that time about the toll HIV was taking on gay, bisexual and other men who have sex with men was deeply troubling to many community members and advocates working at the frontlines.
In order to develop its new Strategic Plan (2016-2021), MSMGF undertook a comprehensive and iterative consultation process with MSMGF members, partners, Board members and staff. We gathered evidence through a series of activities conducted between early 2015 and early 2016. These activities, as well as other strategies gathered through the whole process is outlined in this document.
Resource | Publications,
This case study describes the model and outcomes of the public private partnership (PPP) that has been implemented by the Alliance since 2009 in Yangon, Myanmar. This information and evidence is essential to support and guide possible expansion and replication of this model in efforts to decentralise ART delivery in other contexts, whilst easing the burden on public health facilities. It highlights the collaborative role of the partners; high impact strategies that have contributed to the success of the model; lessons learnt, best practice and patient outcomes; and concludes with recommendations regarding how this model may be improved.
Resource | Publications,
Universal health coverage (UHC) is an aspirational goal that aims for all people to access and use the promotive, preventive, curative, rehabilitative and palliative health services they need that are of sufficient quality and do not cause financial hardship. HIV programmes have, more than any other health programme, served as a trailblazer for UHC at the global and regional levels. They have been characterized by their strong drive in ensuring equity of access to HIV interventions and by their clear focus on the three dimensions that define UHC: providing health services, covering populations and covering costs.
The global HIV response over the past 15 years has been relatively successful: antiretroviral therapy (ART) has been rapidly scaled up; and new HIV infections and AIDS-related deaths have declined. Still, there were an estimated 2.1 million new HIV infections and 1.5 million AIDS-related deaths in 2013. With business as usual approach, these figures are projected to increase in the future. In the post-2015 sustainable development era, there is a need to strengthen and accelerate the HIV response using the UHC agenda to achieve the end of AIDS by 2030.
Resource | Publications,
The increasing trend of annual number of newly reported HIV infection continued in 2015 and reached a record high of 725 cases. Sexual transmission remained the major route of HIV transmission in Hong Kong thus far, while the transmission from other routes including drug injection has been kept at a relatively low level. Overall, Hong Kong is still having a low prevalence level of HIV infection in the general population.
This annual surveillance report is an initiative of Special Preventive Programme, Centre for Health Protection, Department of Health. The report aims to provide strategic information to facilitate planning of services and intervention activities for the prevention, care and control of HIV/AIDS. Following a commentary, data collected from five main components of our surveillance programme (the HIV/AIDS voluntary reporting system, HIV prevalence surveys, sexually transmitted infections caseload statistics, behavioural studies and HIV-1 genotyping studies) were presented as tables and graphs. Findings of the HIV and AIDS Response Indicator Survey (HARiS) and other studies were also included.
Resource | Publications,
2015 confirmed a significant recent trend in the flagship WHO Model List of Essential Medicines with groundbreaking new treatments for hepatitis C and a variety of cancers included in the list despite their high prices. The list also included five new medicines for multidrug resistant tuberculosis (TB), among other updates. Traditionally considered a tool for developing countries to use as a guide for national medicines selection, the WHO Essential Medicines List is increasingly seen as a tool to increase access globally.
Resource | Publications,
Communicable diseases such as HIV, TB and malaria remain among the leading causes of illness, death and impoverishment in our region, and infection levels continue to rise in many settings and populations. Unless focused efforts are undertaken to build on the gains to date, communities that remain vulnerable to neglected tropical diseases such as leprosy, kala-azar and filariasis will continue to be left behind. This report focuses on the historic opportunity for the WHO South-East Asia Region to end the scourge of communicable diseases for good.
Resource | Reviews and Snapshots,
More than 2 million new HIV infections occurred in 2014—two thirds occurred in sub-Saharan Africa. The speed at which new HIV infections are declining needs to accelerate in order to meet the UNAIDS Fast-Track Targets by 2020.
The UNAIDS Fast-Track prevention target is to reduce the number of new HIV infections to fewer than 500 000 annually by 2020, a reduction of 75% over the next few years.
By scaling up both treatment and HIV prevention, and front-loading investments, around 17.6 million new HIV infections can be averted between 2015 and 2030.
By investing in averting new HIV infections, the future costs of treatment will be reduced and HIV prevention and treatment programmes can be sustained.
Resource | Publications,
Despite enormous progress, over half of the world’s new infections last year were among women, children and adolescents. Every day, around 400 children become infected – enough to fill nearly six school buses. Far too many pregnant women living with HIV are still not receiving treatment, putting their own lives, and the lives and futures of their unborn children, at risk. Far too many children have dropped out of treatment, or never received it in the first place.
The situation is especially dire for adolescents – and for adolescent girls most of all.
To end AIDS in children once and for all, we need to focus on both treatment and prevention, with a deeper focus on the life cycle of the child, beginning during pregnancy, in infancy and childhood, and through adolescence.
Resource | Publications,
2016 was a year of consolidating, catalyzing and achieving incredible results, for the International Treatment Preparedness Coalition (ITPC). We pursued our strategic objectives: to mobilize demand for optimal HIV treatment; we supported civil society to challenge unfair barriers that limit access to essential HIV drugs; and we laid the ground for scaled up community monitoring of HIV treatment services. Our approach, of educating communities, and supporting community-based research and advocacy, informs all our programs.
In 2016, we began new projects to educate communities and mobilize them to demand routine viral load testing, as part of our Be Healthy – Know Your Viral Load campaign. Through 13 regional and national workshops we strengthened the capacity of 270 activists from 36 countries. Training included the science of HIV, HIV treatment monitoring and advocacy. National partners went on to sensitize communities on the need for routine viral load testing, and lobby policy makers to adopt and implement the latest WHO guidelines on treatment monitoring.